Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Systematic Development of Bicalutamide Immediate Release Pellets Using Aeroperl and Non-MCC Extruder Aid

Author(s): Hardik Rana*, Hussain Hasan, Mukesh Gohel, Vaishali Thakkar and Tejal Gandhi

Volume 15, Issue 5, 2020

Page: [482 - 492] Pages: 11

DOI: 10.2174/1574885515999200424082315

Price: $65

Abstract

Background: The Microcrystalline Cellulose is called as a gold standard for the manufacture of pellets. The poor disintegration leads to incomplete drug release that restricts the use of MCC in the immediate-release formulation.

Objective: The present work aims to explore non-MCC extruder aid for pellet formulation and solubility modulation potential of Aeroperl® 300 Pharma.

Methods: Bicalutamide (BCL) was selected as a model BCS class-II drug. The solubility of BCL was assessed in different vehicles such as polyethylene glycol, propylene glycol, and Tween by carrying out phase solubility study. The suitable vehicle was selected based on the higher solubility of BCL. The vehicle was further adsorbed on newer adsorbent Aeroperl® 300 Pharma to formulate liquisolid granules. The liquisolid granules were further incorporated into the pellet using mannitol and microcrystalline cellulose as an extruder aid. Box-Behnken design was adopted for the optimization of formulation considering MCC: mannitol ratio, the concentration of HPMC and spheronizer speed as independent factors whereas drug release at 30 min, disintegration time and aspect ratio were selected as dependent variables. The pellets were evaluated for different evaluation parameters.

Results: Propylene glycol was selected for the formulation of liquisolid technique based on the results of the phase solubility study. Propylene glycol containing BCL was adsorbed on Aeroperl 300 Pharma. The optimized batch was selected exploring the Design-Expert software by considering the limits of different responses. Pellet had excellent flowability. Friability was found to be within the range (<1%). Pellets were found to be spherical and had pores on the surfaces.

Conclusion: Liquisolid granules containing newer solubilizer Aeroperl was found to be a promising approach for the improvement in the solubility of the drug. The use of mannitol with MCC has a profound effect on disintegration time, without altering flow property and other parameters. No patents were reported on the combination of Bicalutamide, mannitol and Aeroperl. The critical finding of the present work is to use mannitol as an extruder aid to fasten the disintegration leads to complete drug release within a short period of time. Aeroperl and Mannitol, MCC: mannitol ratio, the concentration of HPMC and spheronizer speed were found to be significant and had the potential effect in pellet formulation.

Keywords: Bicalutamide, liquisolid technique, aeroperl 300 pharma, MCC to mannitol ratio, disintegration, pellets.

« Previous Next »
Graphical Abstract

[1]
Panda SK, Parida KR, Roy H, Talwar P. A current technology for modified release drug delivery system : Multiple-Unit Pellet System (MUPS). Int J Pharm Sci Heal Care 2013; 6(3): 51-63.
[2]
Jyothi J, Doniparthi J. Multiparticulate drug delivery polymers as release retardant materials. Int J Pharm Pharm Sci 2014; 6(10): 1-15.
[3]
Dey NS, Majumdar S, Rao MEB. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2008; 7(3): 1067-75.
[http://dx.doi.org/10.4314/tjpr.v7i3.14692]]
[4]
Thakkar DK, Shiyani B, Patel G, Patel P, Patel R, Chawda Y. Pelletization techniques- a review. Int J Pharm Res 2012; 4(3): 26-35.
[5]
Mehta KA, Rekhi GS, Parikh DM. Handbook of pharmaceutical granulation technologyhandbook of pharmaceutical granulation technology. New York: Informa Healthcare USA, Inc 2005; pp. 333-63.
[http://dx.doi.org/10.1201/9780849354953.ch11]
[6]
Sarkar S, Heng PWS, Liew CV. Insights into the functionality of pelletization aid in pelletization by extrusion-spheronization. Pharm Dev Technol 2013; 18(1): 61-72.
[http://dx.doi.org/10.3109/10837450.2011.621210] [PMID: 21981607]
[7]
Otero-Espinar FJ, Luzardo-Alvarez A, Blanco-Méndez J. Non-MCC materials as extrusion-spheronization aids in pellets production. J Drug Deliv Sci Technol 2010; 20(4): 303-18.
[http://dx.doi.org/10.1016/S1773-2247(10)50047-9]
[8]
Dukić-Ott A, Thommes M, Remon JP, Kleinebudde P, Vervaet C. Production of pellets via extrusion-spheronisation without the incorporation of microcrystalline cellulose: a critical review. Eur J Pharm Biopharm 2009; 71(1): 38-46.
[http://dx.doi.org/10.1016/j.ejpb.2008.08.005] [PMID: 18771727]
[9]
Tripurasundari BP. Review on the production of pellets via extrusion- cellulose. Int J Pharm Rev Res 2012; 2(1): 1-10.
[10]
Otero-espinar FJ. Non-MCC materials as extrusion- spheronization aids in pellets production Non-MCC materials as extrusion-spheronization aids in pellets production. J Drug Deliv Sci Technol 2010; 20(4): 303-18.
[http://dx.doi.org/10.1016/S1773-2247(10)50047-9]
[11]
Nidhi K, Indrajeet S, Khushboo M, Gauri K, Sen DJ. Hydrotropy: a promising tool for solubility enhancement: a review. Int J Drug Dev Res 2011; 3(2): 26-33.
[12]
Ali MT, Fule R, Sav A, Amin P. Porous starch: a novel carrier for solubility enhancement of carbamazepine. AAPS PharmSciTech 2013; 14(3): 919-26.
[http://dx.doi.org/10.1208/s12249-013-9985-6] [PMID: 23715951]
[13]
Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012; 63: 185-98.
[http://dx.doi.org/10.1146/annurev-med-040210-162544] [PMID: 21888516]
[14]
Evonik industries. Technical information on AEROPERL® 300 pharma improving the dissolution of poorly soluble APIs table of contents. Available from: http://www.aerosil.com/product/aerosil/downloads/ti-1414-aeroperl-300-pharma-en.pdf
[15]
Paudel A, Worku ZA, Meeus J, Guns S, Van den Mooter G. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int J Pharm 2013; 453(1): 253-84.
[http://dx.doi.org/10.1016/j.ijpharm.2012.07.015] [PMID: 22820134]
[16]
Azad M, Moreno J, Davé R. Stable and fast-dissolving amorphous drug composites preparation via impregnation of neusilin® UFL2. J Pharm Sci 2018; 107(1): 170-82.
[http://dx.doi.org/10.1016/j.xphs.2017.10.007] [PMID: 29031953]
[17]
Pawar JN, Desai HR, Moravkar KK, Khanna DK, Amin PD. Exploring the potential of porous silicas as a carrier system for dissolution rate enhancement of artemether. Asian J Pharm Sci 2016; 11(6): 760-70.
[http://dx.doi.org/10.1016/j.ajps.2016.06.002]]
[18]
Spireas S. Liquisolid system and methods of preparing same U.S.: United States Patent; US 6,423,339 B1, 2002.
[19]
Lu M, Xing H, Jiang J, et al. Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci 2017; 12(2): 115-23.
[http://dx.doi.org/10.1016/j.ajps.2016.09.007] [PMID: 32104320]
[20]
El-Say KM, Samy AM, Fetouh MI. Formulation and evaluation of Rofecoxib liquisolid tablets. Int J Pharm Sci Rev Res 2010; 3(1): 135-42.
[21]
Chella N, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm Sin B 2012; 2(5): 502-8.
[http://dx.doi.org/10.1016/j.apsb.2012.07.005]
[22]
Burra S, Yamsani M, Vobalaboina V. The liquisolid technique: an overview. Braz J Pharm Sci 2011; 47(3): 475-82.
[http://dx.doi.org/10.1590/S1984-82502011000300005]
[23]
Prajapati ST, Bulchandani HH, Patel DM, Dumaniya SK, Patel CN. Formulation and evaluation of liquisolid compacts for olmesartan medoxomil. J Drug Deliv 2013; 2013(5)870579
[http://dx.doi.org/10.1155/2013/870579] [PMID: 24232077]
[24]
Chatchawalsaisin J, Podczeck F, Newton JM. The preparation by extrusion/spheronization and the properties of pellets containing drugs, microcrystalline cellulose and glyceryl monostearate. Eur J Pharm Sci 2005; 24(1): 35-48.
[http://dx.doi.org/10.1016/j.ejps.2004.09.008] [PMID: 15626576]
[25]
Patel H, Patel K, Tiwari S, Pandey S, Shah S, Gohel M. Quality by Design (QbD) approach for development of co-processed excipient pellets (MOMLETS) by extrusion-spheronization technique. Recent Pat Drug Deliv Formul 2016; 10(3): 192-206.
[http://dx.doi.org/10.2174/1872211310666160709193540] [PMID: 27396400]
[26]
Latha S, Sivaranjani G, Dhanasekaran D. Response surface methodology: a non-conventional statistical tool to maximize the throughput of streptomyces species biomass and their bioactive metabolites. Crit Rev Microbiol 2017; 43(5): 567-82.
[http://dx.doi.org/10.1080/1040841X.2016.1271308] [PMID: 28129718]
[27]
Wang J, Kan S, Chen T, Liu J. Application of Quality by Design (QbD) to formulation and processing of naproxen pellets by extrusion-spheronization. Pharm Dev Technol 2015; 20(2): 246-56.
[http://dx.doi.org/10.3109/10837450.2014.908300] [PMID: 25069591]
[28]
Prabhu D. Optimization of process parameters using response surface methodology for removal of phenol by nano zero valent iron impregnated cashew nut shell. Int J Pharm Pharm Sci 2015; 7(4): 2-7.
[29]
Muley S, Nandgude T, Poddar S. Extrusion – spheronization a promising pelletization technique : in-depth review. Asian J Pharm Sci 2016; 11(6): 684-99.
[http://dx.doi.org/10.1016/j.ajps.2016.08.001]
[30]
de Barros JMS, Lechner T, Charalampopoulos D, Khutoryanskiy VV, Edwards AD. Enteric coated spheres produced by extrusion/spheronization provide effective gastric protection and efficient release of live therapeutic bacteria. Int J Pharm 2015; 493(1-2): 483-94.
[http://dx.doi.org/10.1016/j.ijpharm.2015.06.051] [PMID: 26188314]
[31]
Dhandapani NV, Shrestha A. Pelletization by extrusion-spheronization: a detailed review. All Res J Biol 2012; 3(2): 10-23.
[32]
Vo AQ, Feng X, Morott JT, et al. A novel floating controlled release drug delivery system prepared by hot-melt extrusion. Eur J Pharm Biopharm 2016; 98: 108-21.
[http://dx.doi.org/10.1016/j.ejpb.2015.11.015] [PMID: 26643801]
[33]
Sharma K, Hallan SS, Lal B, Bhardwaj A, Mishra N. Development and characterization of floating spheroids of atorvastatin calcium loaded NLC for enhancement of oral bioavailability. Artif Cells Nanomed Biotechnol 2016; 44(6): 1448-56.
[http://dx.doi.org/10.3109/21691401.2015.1041637] [PMID: 25960179]
[34]
Loka NC, Saripella KK, Pinto CA, Neau SH. Use of extrusion aids for successful production of Kollidon® CL-SF pellets by extrusion-spheronization. Drug Dev Ind Pharm 2018; 44(4): 632-42.
[http://dx.doi.org/10.1080/03639045.2017.1405975] [PMID: 29183166]
[35]
Zhang S, Xia Y, Yan H, Zhang Y, Zhang W, Liu J. The water holding ability of powder masses: Characterization and influence on the preparation of pellets via extrusion/spheronization. Powder Technol 2016; 301: 940-8.
[http://dx.doi.org/10.1016/j.powtec.2016.07.030]
[36]
Pezzini BR, Beringhs AO, Ferraz HG, Silva MAS, Stulzer HK, Sonaglio D. Liquisolid technology applied to pellets: evaluation of the feasibility and dissolution performance using felodipine as a model drug. Chem Eng Res Des 2016; 110: 62-9.
[http://dx.doi.org/10.1016/j.cherd.2016.01.037]
[37]
Kilor VA, Sapkal NP, Awari JG, Shewale BD. Development and characterization of enteric-coated immediate-release pellets of aceclofenac by extrusion/spheronization technique using κ-carrageenan as a pelletizing agent. AAPS PharmSciTech 2010; 11(1): 336-43.
[http://dx.doi.org/10.1208/s12249-010-9389-9] [PMID: 20195805]
[38]
Ibrahim MA, El-Badry M. Formulation of immediate release pellets containing famotidine solid dispersions. Saudi Pharm J 2014; 22(2): 149-56.
[http://dx.doi.org/10.1016/j.jsps.2013.01.011] [PMID: 24648827]
[39]
Patel N, Thakkar V, Moradiya P, Gandhi T, Gohel M. Optimization of curcumin loaded vaginal in-situ hydrogel by box- behnken statistical design for contraception. J Drug Deliv Sci Technol 2015; 29(1): 55-68.
[http://dx.doi.org/10.1016/j.jddst.2015.06.002]

Rights & Permissions Print Cite
Article Metrics
13
© 2024 Bentham Science Publishers | Privacy Policy